Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Assets (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Current Assets for 7 consecutive years, with $996.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 7.19% to $996.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $996.7 million through Dec 2025, up 7.19% year-over-year, with the annual reading at $996.7 million for FY2025, 7.19% up from the prior year.
  • Current Assets hit $996.7 million in Q4 2025 for Immunocore Holdings, down from $1.0 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.0 billion in Q3 2025 to a low of $354.2 million in Q4 2021.
  • Historically, Current Assets has averaged $830.2 million across 5 years, with a median of $948.6 million in 2025.
  • Biggest five-year swings in Current Assets: skyrocketed 75.84% in 2024 and later grew 1.68% in 2025.
  • Year by year, Current Assets stood at $354.2 million in 2021, then increased by 29.79% to $459.6 million in 2022, then rose by 15.05% to $528.8 million in 2023, then soared by 75.84% to $929.9 million in 2024, then grew by 7.19% to $996.7 million in 2025.
  • Business Quant data shows Current Assets for IMCR at $996.7 million in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.